NCT05564377 — drugset

Summary

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation. ComboMATCH is designed to match patients to a treatment that may work to control their tumor and may help doctors plan better treatment for patients with locally advanced or advanced solid tumors.

Timeline

Start: 2023-04-07
Primary completion: 2030-07-01
Completion: 2030-07-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Alpelisib	Small molecule	—	Oral
Subject	Binimetinib	Small molecule	—	Oral
Subject	Fulvestrant	Small molecule	—	Intramuscular
Subject	Ipatasertib	Small molecule	—	Oral
Subject	Neratinib	Small molecule	—	Oral
Subject	Nilotinib	Small molecule	—	Oral
Subject	Olaparib	Small molecule	—	Oral
Subject	Palbociclib	Small molecule	—	Oral
Subject	Panitumumab	Monoclonal antibody	—	Intravenous
Subject	Selumetinib	Small molecule	—	Oral
Subject	Sotorasib	Small molecule	—	Oral
Background	Leucovorin	Small molecule	—	Intravenous
Background	Oxaliplatin	Small molecule	—	Intravenous
Background	Paclitaxel	Small molecule	—	Intravenous
Background	fluorouracil	Small molecule	—	Intravenous

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Summary

Timeline

Drugs

Indications